A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...

U.S. stocks closed higher on Monday and the Dow and S&P 500 posted record highs, although the gains were just marginal, as investors ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

In this clip, from Forbes 30 Under 30 Summit, Ken Frazier explains the benefits of investing in your economy. Frazier is an ...

Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...

And the agency expanded the approval of bimekizumab (Bimzelx) to include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, UCB Announced.

More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...

Managing supply chain complexities in biotechnology, cell and gene therapy, medical devices, over-the-counter medicines and more, Kinaxis customers include some of the world's top pharma companies ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), ...